Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1681)

CANCELLATION OF GRANT OF SHARE OPTIONS

References is made to the announcement of Consun Pharmaceutical Group Limited (the "Company") dated 1 June 2020 in relation to the grant of share options to certain grantees to subscribe for an aggregate of 1,688,000 ordinary shares of HKD0.1 each of the Company under the share option scheme of the Company adopted on 2 December 2013 (the "Announcement"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

Pursuant to Rule 10.06(3) of the Listing Rules, the Company may not make a new issue of Shares or announce a proposed new issue of Shares for a period of 30 days after any purchase by it of its Shares. The Share Options carry rights to subscribe for the Company's Shares and fall within the definition of "shares" under Rule 10.06(6)(c) of the Listing Rules. The purported Grant of Share Options has not been accepted by the respective Grantees and has not been materialised. The purported Grant of Share Options has been cancelled accordingly by the Company.

The Company will make an announcement in relation to the grant of share options at another time when the Company can comply with Rule 10.06 of the Listing Rules.

By order of the Board

Consun Pharmaceutical Group Limited

AN Yubao

Chairman

Hong Kong, 4 June 2020

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian and Professor ZHU Quan as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.